SynthesisReviews in cardiovascular medicine2024
Prognostic Value of Serum Neutrophil Gelatinase-Associated Lipocalin in Acute Heart Failure: A Meta-Analysis.
Synthesis in Reviews in cardiovascular medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The Adipokine Axis in Heart Failure: Linking Obesity, Sarcopenia and Cardiac Dysfunction in HFpEF.International journal of molecular sciences · 2026Review
- Biomarkers in Heart Failure: A Review and a Wish.International journal of molecular sciences · 2025Review
- Novel and established biomarkers to complement risk scores in patients with acute decompensated heart failure - a pilot study.American heart journal plus : cardiology research and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neutrophil gelatinase-associated lipocalin (NGAL) is not only a sensitive marker of acute kidney injury but may also be a prognostic marker of acute heart failure (AHF). This study aimed to investigate the relationship between serum NGAL and all-cause death (ACD) and the composite outcome of ACD or AHF readmissions in patients with AHF. Methods: The Embase, Cochrane Library, and PubMed databases were searched for articles focusing on serum NGAL and ACD and the composite outcome of ACD or AHF readmissions in patients with AHF. The hazard ratios (HRs) were pooled with random-effects models. Results: The results from 2428 patients from seven studies were pooled in this article. Higher NGAL was relevant to an increased risk of ACD (HR, 1.89; 95% CI, 1.38 to 2.61) and the composite outcome of ACD or AHF readmissions (HR, 2.92; 95% CI, 1.62 to 5.27) in patients with AHF. Conclusions: Serum NGAL has prognostic value for ACD and the composite outcome of ACD or AHF readmissions in AHF. The PROSPERO registration: CRD42022322057, https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022322057.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.